Human monoclonal antibody developed against ovarian cancer cell surface antigen

Tandra R. Chaudhuri, Kurt R. Zinn, J. Steven Morris, Gregory A. McDonald, Alfred S. Llorens, Tuhin K Chaudhuri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. Murine monoclonal antibodies (MoAb) potentially can be used in the radioimmunodetection and radioimmunotherapy of cancer. However, the administration of these radiopharmaceuticals to humans often leads to induction of human anti‐murine antibodies (HAMA). HAMA has many disadvantages, which could decrease efficacy of the murine MoAb. The purpose of this work was to produce human monoclonal antibody against a human ovarian cancer cell surface antigen (OCCSA), which was not present in normal ovarian cells. This 200‐kilodalton OCCSA also was used in the present study for characterizing the human monoclonal antibody. Methods. Human monoclonal antibodies were produced in vitro by fusion of mutant myeloma cells, selected from GM1500, with human lymphoid cells immunized in vitro with purified OCCSA. The human monoclonal antibody was characterized using the following techniques: sodium dodecyl sulfate‐polyacrylamide gel electrophoresis (SDS‐PAGE), native‐PAGE, Western blotting followed by protein‐A gold staining, immunodiffusion assays, and fluorescent antibody assays. Results. Human monoclonal antibody, TC5 (immunoglobulin G1), was produced and purified. It was found to be specific for ovarian cancer, while also reacting with an early stage breast cancer. TC5 did not react with any normal (i.e., nonneoplastic) cells of the ovary, uterus, cervix, endocervix, or fallopian tube, nor did it react with normal lung, heart, pancreas, liver, or breast tissue. Conclusion. Human‐human hybridomas produced human monoclonal antibody against OCCSA. The human monoclonal antibody, TC5, was specific for ovarian and breast cancer. TC5 did not react with any normal tissue tested. Future work will focus on the in vivo characterization of the human monoclonal antibody, after labeling with radionuclides. Cancer 1994; 73:1098–104.

Original languageEnglish (US)
Pages (from-to)1098-1104
Number of pages7
JournalCancer
Volume73
Issue number3 S
DOIs
StatePublished - 1994

Fingerprint

Surface Antigens
Ovarian Neoplasms
Monoclonal Antibodies
Antibodies
Radioimmunodetection
Breast Neoplasms
Radioimmunotherapy
Fallopian Tubes
Radiopharmaceuticals
Immunodiffusion
Hybridomas
Cervix Uteri
Radioisotopes
Gold
Electrophoresis
Immunoglobulins
Pancreas
Ovary
Neoplasms
Breast

Keywords

  • human monoclonal antibody
  • hybridoma
  • ovarian cancer
  • radioimmunodiagnosis
  • radiopharmaceuticals

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chaudhuri, T. R., Zinn, K. R., Steven Morris, J., McDonald, G. A., Llorens, A. S., & Chaudhuri, T. K. (1994). Human monoclonal antibody developed against ovarian cancer cell surface antigen. Cancer, 73(3 S), 1098-1104. https://doi.org/10.1002/1097-0142(19940201)73:3+<1098::AID-CNCR2820731350>3.0.CO;2-A

Human monoclonal antibody developed against ovarian cancer cell surface antigen. / Chaudhuri, Tandra R.; Zinn, Kurt R.; Steven Morris, J.; McDonald, Gregory A.; Llorens, Alfred S.; Chaudhuri, Tuhin K.

In: Cancer, Vol. 73, No. 3 S, 1994, p. 1098-1104.

Research output: Contribution to journalArticle

Chaudhuri, TR, Zinn, KR, Steven Morris, J, McDonald, GA, Llorens, AS & Chaudhuri, TK 1994, 'Human monoclonal antibody developed against ovarian cancer cell surface antigen', Cancer, vol. 73, no. 3 S, pp. 1098-1104. https://doi.org/10.1002/1097-0142(19940201)73:3+<1098::AID-CNCR2820731350>3.0.CO;2-A
Chaudhuri, Tandra R. ; Zinn, Kurt R. ; Steven Morris, J. ; McDonald, Gregory A. ; Llorens, Alfred S. ; Chaudhuri, Tuhin K. / Human monoclonal antibody developed against ovarian cancer cell surface antigen. In: Cancer. 1994 ; Vol. 73, No. 3 S. pp. 1098-1104.
@article{f3e05d7ccdbd4e9c9e6ea2e03e466d83,
title = "Human monoclonal antibody developed against ovarian cancer cell surface antigen",
abstract = "Background. Murine monoclonal antibodies (MoAb) potentially can be used in the radioimmunodetection and radioimmunotherapy of cancer. However, the administration of these radiopharmaceuticals to humans often leads to induction of human anti‐murine antibodies (HAMA). HAMA has many disadvantages, which could decrease efficacy of the murine MoAb. The purpose of this work was to produce human monoclonal antibody against a human ovarian cancer cell surface antigen (OCCSA), which was not present in normal ovarian cells. This 200‐kilodalton OCCSA also was used in the present study for characterizing the human monoclonal antibody. Methods. Human monoclonal antibodies were produced in vitro by fusion of mutant myeloma cells, selected from GM1500, with human lymphoid cells immunized in vitro with purified OCCSA. The human monoclonal antibody was characterized using the following techniques: sodium dodecyl sulfate‐polyacrylamide gel electrophoresis (SDS‐PAGE), native‐PAGE, Western blotting followed by protein‐A gold staining, immunodiffusion assays, and fluorescent antibody assays. Results. Human monoclonal antibody, TC5 (immunoglobulin G1), was produced and purified. It was found to be specific for ovarian cancer, while also reacting with an early stage breast cancer. TC5 did not react with any normal (i.e., nonneoplastic) cells of the ovary, uterus, cervix, endocervix, or fallopian tube, nor did it react with normal lung, heart, pancreas, liver, or breast tissue. Conclusion. Human‐human hybridomas produced human monoclonal antibody against OCCSA. The human monoclonal antibody, TC5, was specific for ovarian and breast cancer. TC5 did not react with any normal tissue tested. Future work will focus on the in vivo characterization of the human monoclonal antibody, after labeling with radionuclides. Cancer 1994; 73:1098–104.",
keywords = "human monoclonal antibody, hybridoma, ovarian cancer, radioimmunodiagnosis, radiopharmaceuticals",
author = "Chaudhuri, {Tandra R.} and Zinn, {Kurt R.} and {Steven Morris}, J. and McDonald, {Gregory A.} and Llorens, {Alfred S.} and Chaudhuri, {Tuhin K}",
year = "1994",
doi = "10.1002/1097-0142(19940201)73:3+<1098::AID-CNCR2820731350>3.0.CO;2-A",
language = "English (US)",
volume = "73",
pages = "1098--1104",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3 S",

}

TY - JOUR

T1 - Human monoclonal antibody developed against ovarian cancer cell surface antigen

AU - Chaudhuri, Tandra R.

AU - Zinn, Kurt R.

AU - Steven Morris, J.

AU - McDonald, Gregory A.

AU - Llorens, Alfred S.

AU - Chaudhuri, Tuhin K

PY - 1994

Y1 - 1994

N2 - Background. Murine monoclonal antibodies (MoAb) potentially can be used in the radioimmunodetection and radioimmunotherapy of cancer. However, the administration of these radiopharmaceuticals to humans often leads to induction of human anti‐murine antibodies (HAMA). HAMA has many disadvantages, which could decrease efficacy of the murine MoAb. The purpose of this work was to produce human monoclonal antibody against a human ovarian cancer cell surface antigen (OCCSA), which was not present in normal ovarian cells. This 200‐kilodalton OCCSA also was used in the present study for characterizing the human monoclonal antibody. Methods. Human monoclonal antibodies were produced in vitro by fusion of mutant myeloma cells, selected from GM1500, with human lymphoid cells immunized in vitro with purified OCCSA. The human monoclonal antibody was characterized using the following techniques: sodium dodecyl sulfate‐polyacrylamide gel electrophoresis (SDS‐PAGE), native‐PAGE, Western blotting followed by protein‐A gold staining, immunodiffusion assays, and fluorescent antibody assays. Results. Human monoclonal antibody, TC5 (immunoglobulin G1), was produced and purified. It was found to be specific for ovarian cancer, while also reacting with an early stage breast cancer. TC5 did not react with any normal (i.e., nonneoplastic) cells of the ovary, uterus, cervix, endocervix, or fallopian tube, nor did it react with normal lung, heart, pancreas, liver, or breast tissue. Conclusion. Human‐human hybridomas produced human monoclonal antibody against OCCSA. The human monoclonal antibody, TC5, was specific for ovarian and breast cancer. TC5 did not react with any normal tissue tested. Future work will focus on the in vivo characterization of the human monoclonal antibody, after labeling with radionuclides. Cancer 1994; 73:1098–104.

AB - Background. Murine monoclonal antibodies (MoAb) potentially can be used in the radioimmunodetection and radioimmunotherapy of cancer. However, the administration of these radiopharmaceuticals to humans often leads to induction of human anti‐murine antibodies (HAMA). HAMA has many disadvantages, which could decrease efficacy of the murine MoAb. The purpose of this work was to produce human monoclonal antibody against a human ovarian cancer cell surface antigen (OCCSA), which was not present in normal ovarian cells. This 200‐kilodalton OCCSA also was used in the present study for characterizing the human monoclonal antibody. Methods. Human monoclonal antibodies were produced in vitro by fusion of mutant myeloma cells, selected from GM1500, with human lymphoid cells immunized in vitro with purified OCCSA. The human monoclonal antibody was characterized using the following techniques: sodium dodecyl sulfate‐polyacrylamide gel electrophoresis (SDS‐PAGE), native‐PAGE, Western blotting followed by protein‐A gold staining, immunodiffusion assays, and fluorescent antibody assays. Results. Human monoclonal antibody, TC5 (immunoglobulin G1), was produced and purified. It was found to be specific for ovarian cancer, while also reacting with an early stage breast cancer. TC5 did not react with any normal (i.e., nonneoplastic) cells of the ovary, uterus, cervix, endocervix, or fallopian tube, nor did it react with normal lung, heart, pancreas, liver, or breast tissue. Conclusion. Human‐human hybridomas produced human monoclonal antibody against OCCSA. The human monoclonal antibody, TC5, was specific for ovarian and breast cancer. TC5 did not react with any normal tissue tested. Future work will focus on the in vivo characterization of the human monoclonal antibody, after labeling with radionuclides. Cancer 1994; 73:1098–104.

KW - human monoclonal antibody

KW - hybridoma

KW - ovarian cancer

KW - radioimmunodiagnosis

KW - radiopharmaceuticals

UR - http://www.scopus.com/inward/record.url?scp=0028125843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028125843&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19940201)73:3+<1098::AID-CNCR2820731350>3.0.CO;2-A

DO - 10.1002/1097-0142(19940201)73:3+<1098::AID-CNCR2820731350>3.0.CO;2-A

M3 - Article

C2 - 8306253

AN - SCOPUS:0028125843

VL - 73

SP - 1098

EP - 1104

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3 S

ER -